Added benefit of eribulin in breast cancer is not proven
Eribulin (trade name: Halaven) was approved in March 2011 for women with locally advanced or metastasizing breast cancer in whom the disease has progressed despite prior drug therapy.
In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether eribulin offers an added benefit compared with the present standard therapy.
According to the results of the assessment, the currently available evidence provides "hints" that eribulin may increase survival time in patients for whom taxanes or anthracyclines are no longer an option. However, it is unclear how many more weeks or months patients can survive. No survival advantage was shown in patients who can still be treated with taxanes or anthracyclines. At the same time, due to a lack of suitable data it cannot be excluded with sufficient certainty that eribulin causes greater harm in the form of side effects. Overall, IQWiG therefore concludes that an added benefit of eribulin is not proven.
G-BA specifies appropriate comparator therapy
According to the legal ordinance, benefit assessments must follow the approval status. This refers both to the new drug to be evaluated and to the therapies used in the comparator groups.
Eribulin is approved for patients in whom the disease has progressed further, despite having received at least two cycles of a taxane and anthracycline containing chemotherapy (unless these treatments were considered unsuitable). As appropriate comparator therapies, the Federal Joint Committee (G-BA) has specified either monotherapy with capecitabine, 5-fluorouracil, or vinorelbine or renewed therapy with taxanes or anthracyclines, insofar as this is an option for patients.
The pharmaceutical company followed this specification of the appropriate comparator therapy. However, by the wording of the research question and the inclusion criteria of the dossier, the company also allowed other treatments as a comparator therapy for eribulin.
One study included in the assessment
One relevant study was available for the early benefit assessment, an approval study on eribulin (EMBRACE). However, drugs that were not a component of the appropriate comparator therapy were also used in this study. 18% of patients even received treatment that is not approved in Germany for the indication investigated (gemcitabine monotherapy).
Overall, only 69% of patients in the comparator group were treated according to the specifications of the G-BA. Nevertheless, in the dossier the manufacturer uses the results of all patients (overall population). This is an approach that IQWiG cannot accept.
No survival advantage in patients who can still be treated with taxanes or anthracyclines
Data on overall survival and side effects (adverse events), but not on quality of life, were analysed in the study, so that per se no conclusions about the latter outcome are possible.
For the outcome "overall survival", separate data were available for the sub-population treated with the appropriate comparator therapy. As the analysis showed, patients in the eribulin group for whom treatment with taxanes or anthracyclines could still be an option did not survive longer than patients who received these treatment alternatives. An added benefit is therefore not proven.
"Hint" of an increase in survival in patients for whom taxanes or anthracyclines are no longer an option
The situation is different in patients for whom taxanes or anthracyclines are no longer an option. The data show a survival advantage here, at least for the first time point of analysis. In contrast, statistically significant differences were no longer observed between treatment groups at a second, later time point of analysis. It cannot be calculated exactly how many weeks or months longer patients receiving eribulin survived. However, the difference in the study was not more than a few months.
From the data analysed, IQWiG initially infers a "hint" of an added benefit in patients for whom treatment with taxanes or anthracyclines is no longer an option; the extent of this added benefit is unquantifiable but can at best be classified as "considerable".
No separate data on adverse events in the sub-population
In contrast to the outcome "overall survival", data on side effects (adverse events) were only available for the overall population; no separate data were provided for the sub-population treated with one of the appropriate comparator therapies specified. In its assessment, IQWiG additionally investigated the data for the overall population in order to obtain an impression of potential harm caused by the interventions.
According to the results, both the overall rate of adverse events and the rate of severe adverse events were statistically significantly higher in the eribulin group than in the comparator group. IQWiG infers from these results that greater harm from eribulin cannot be excluded with sufficient certainty for the sub-population investigated in the dossier assessment.
Negative effects may outweigh positive ones
Overall IQWiG cannot infer an added benefit of eribulin from the data available. This also applies to the sub-group of patients for whom taxanes or anthracyclines are no longer an option. This is because it cannot be excluded that the negative effects (severe adverse events) outweigh the positive effects (survival). It cannot be excluded that eribulin may even be more harmful than beneficial in patients who could still be treated with taxanes or anthracyclines.
G-BA decides on the extent of added benefit
The procedure for inferring the overall conclusion on the extent of added benefit is a proposal from IQWiG. The G-BA, which has opened a formal commenting procedure, decides on the extent of added benefit.
The following extract (PDF, 186 kB) provides an overview of the results of IQWiG's benefit assessment. The website gesundheitsinformation.de, which is issued by IQWiG, provides easily understandable brief information (German version).
- Cabazitaxel can offer an advantage in certain patients May 29, 2012 | not rated yet | 0
- Added benefit of linagliptin is not proven Jan 06, 2012 | not rated yet | 0
- Abiraterone: Indication of considerable added benefit in certain patients Jan 06, 2012 | not rated yet | 0
- Fingolimod: 'Hint' of advantages in a small group of patients Jul 05, 2012 | not rated yet | 0
- Collagenase for Dupuytren's contracture: Added benefit not proven Jul 12, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
How can there be a term called "intestinal metaplasia" of stomach
23 hours ago Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
- More from Physics Forums - Medical Sciences
More news stories
The gap between life expectancy in patients with a mental illness and the general population has widened since 1985 and efforts to reduce this gap should focus on improving physical health, suggest researchers in a paper ...
Cancer 11 hours ago | not rated yet | 0
By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces ...
Cancer 12 hours ago | not rated yet | 0
A novel transcriptome-based classification of colon cancer that improves the current disease stratification based on clinicopathological variables and common DNA markers is presented in a study published in PLOS Medicine this w ...
Cancer 13 hours ago | not rated yet | 0
A study of veterans at high risk for developing lung cancer shows that low-dose computed tomography (LDCT) can be highly effective in helping clinicians spot tiny lung nodules which, in a small number of patients, may indicate ...
Cancer 14 hours ago | not rated yet | 0
An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.
Cancer 16 hours ago | not rated yet | 0
Is it permissible to harm one to save many? Those who tend to say "yes" when faced with this classic dilemma are likely to be deficient in a specific kind of empathy, according to a report published in the scientific journal ...
1 hour ago | not rated yet | 0 |
Phthalates: Study links chemicals widely found in plastics, processed food to elevated blood pressure in children, teens
Plastic additives known as phthalates (pronounced THAL-ates) are odorless, colorless and just about everywhere: They turn up in flooring, plastic cups, beach balls, plastic wrap, intravenous tubing and—according to the ...
2 hours ago | not rated yet | 1 |
(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...
18 hours ago | 4.2 / 5 (5) | 0 |
(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...
16 hours ago | 4.9 / 5 (14) | 0 |
Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.
18 hours ago | 4.6 / 5 (7) | 0 |
Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...
13 hours ago | 5 / 5 (5) | 0 |